This European pharmaceutical company has been operating for several decades, focusing on improving patient health and quality of life through innovative solutions. They specialize in developing Rx products, particularly in the areas of pain management, respiratory conditions, autoimmune diseases, and urogynecology. Their commitment to research and development involves collaborations with scientific partners to create new solutions. Their product portfolio includes oral and injectable dosage forms, and they hold GMP approvals in both the EU and the US. The company's dedication to a positive work environment is evident in their Great Place to Work certification. They actively seek collaborations and licensing agreements with other pharmaceutical and biotechnology companies, demonstrating their commitment to innovation and growth.
Manufacturer usually replies in nan days
Oxybutynin is a medication used to treat overactive bladder. Suppliers market it as oxybutynin oral tablets, transdermal patches, topical gels and it is available as immediate and delayed-release formulations.
The drug was first approved for medical use in 1975, and by now has reached widespread use, with over 6 million prescriptions registered yearly in the U.S. alone. Multiple manufacturing companies and drug vendors populate the global oxybutynin market, including major suppliers such as Sanofi-Aventis, Mylan, Accord Healthcare, and many others.
Suppliers market both generic and trade name oxybutynin medications. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.
The retail prices per 60 (5mg) tablets of oxybutynin fall into an approximate range of 7.50 EUR to 10.00 EUR.